MRK Merck & Company Inc. (new)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 24 January 2020 Koneksa Health Announces Study Publication Validating mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring

   NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Koneksa Health, the leader in developing and implementing patient-focused digital biomarkers for drug development, along with Merck & Co, Inc. (NYSE:MRK) announced the

2. 23 January 2020 Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

   Collaboration includes the National Institutes of Health (NIH) and leverages flexibility of Moderna's mRNA vaccine technology Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA

3. 23 January 2020 Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

   Approval Based on Results of KEYNOTE-426, Where KEYTRUDA® in Combination with Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib Renal cell carcinoma (RCC) is the most common form of kidney

4. 22 January 2020 BriaCell Invited to Present at Mount Sinai's Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

   BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

5. 21 January 2020 FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

   Submission Based on PROfound, the First Phase 3 Trial Evaluating a Targeted Treatment in Biomarker-Selected Prostate Cancer Patients AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada,

6. 18 January 2020 Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians

   ORLANDO, Fla., Jan. 18, 2020 /PRNewswire/ -- Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the results of a comprehensive study of wellbeing and mental health

7. 16 January 2020 Merck Completes Acquisition of ArQule

   Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of ArQule,

8. 13 January 2020 FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review

    Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in Women Regardless of Their Biomarker Status Who Responded to Platinum-Based Chemotherapy AstraZeneca and Merck (NYSE:MRK), known as MSD

9. 13 January 2020 BriaCell Provides Update on Remarkable Responder

   Patient initially identified September 19, 2019

10. 12 January 2020 Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

    mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be

11. 09 January 2020 BriaCell Outlines New High Responding Patient Group 'Biomarker' Based on Cancer Grade

    BriaCell has identified a patient population Biomarker with high rate of clinical benefit from the treatments based on ‘Breast Cancer Grade';Breast Cancer Grade correlates with response in bot

12. 08 January 2020 FDA Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy

    KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Certain Patients With High-Risk, Non-Muscle Invasive Bladder Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the

13. 06 January 2020 Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

    Phase 3 KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint of Overall Survival; Results to be Presented at Upcoming Medical Meeting Merck (NYSE:MRK), known as MSD outside the

14. 06 January 2020 Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., ("Taiho") and Astex

15. 03 January 2020 Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on

16. 02 January 2020 BriaCell Completes Share Consolidation

    BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 02, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

17. 02 January 2020 Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories,

18. 30 December 2019 LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

    LYNPARZA Reduced the Risk of Disease Progression or Death by 47% Compared to Placebo in Patients Whose Disease Had Not Progressed On at Least 16 Weeks of a First-Line Platinum-Based Chemotherapy Regimen Only PARP

19. 24 December 2019 BriaCell Therapeutics Corp. Announces Share Consolidation

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 24, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

20. 20 December 2019 NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Dec. 20, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO®, or Zaire Ebola virus vaccine V920

21. 20 December 2019 Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)

    Action Represents Another Milestone for the Global Partnership Against Ebola Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has

22. 20 December 2019 Merck's KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer

    KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H) Tumors in Japan Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's

23. 17 December 2019 FDA Oncologic Drugs Advisory Committee (ODAC) Recommends KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 9-4 in favor of recommending

24. 17 December 2019 Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare

    Strategic Transaction Benefits and Improves Aquaculture Health and Performance Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its

25. 17 December 2019 LYNPARZA® (olaparib) Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer That Has Not Progressed on Platinum-Based Chemotherapy

    Oncologic Drugs Advisory Committee Voted That LYNPARZA Demonstrated a Favorable Benefit-Risk Profile for Patients Based on Phase 3 POLO Trial Results AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United

26. 17 December 2019 Merck Begins Tender Offer to Acquire ArQule

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of ArQule, Inc. (NASDAQ:ARQL). On

27. 17 December 2019 BriaCell to Present at Biotech Showcase™ 2020 in San Francisco

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 17, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

28. 13 December 2019 BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®

    Safety and early efficacy data were presented on December 12th at 6:00 p.m. ET from the clinical trials of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer:

29. 11 December 2019 Moderna Announces Key 2020 Investor and Analyst Events

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its key

30. 10 December 2019 François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

31. 09 December 2019 Merck to Acquire ArQule, Advancing Leadership in Oncology

    Acquisition Further Diversifies Merck's Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies Merck (NYSE:MRK), known as MSD outside the United States and Canada, and ArQule,

32. 05 December 2019 LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer

    AstraZeneca and Merck's LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Versus Placebo in BRCAm Advanced Ovarian Cancer Following Response to Platinum-Based Chemotherapy Only PARP Inhibitor Approved

33. 02 December 2019 Merck to Present at the Evercore ISI HealthCONx Conference 2019

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, chief marketing officer for Merck is scheduled to present during a fireside chat at the Evercore ISI HealthCONx

34. 02 December 2019 FDA Grants Priority Review to Merck's Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)

    Application Based on Results from Phase 2 KEYNOTE-057 Trial, to be Discussed at December FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today

35. 26 November 2019 Merck's KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

    Third Approval for KEYTRUDA in First-Line NSCLC in China in Less Than One Year Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been

36. 25 November 2019 New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors

    KENILWORTH, N.J. and NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Merck (NYSE:MRK) known as MSD outside the United States and Canada, in partnership with Prevention Access Campaign today launched Owning HIV: Young Adults and

37. 20 November 2019 European Commission Approves Two New Regimens of Merck's KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

    KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the First-Line Treatment of Head and Neck Cancer as Monotherapy or in Combination with Chemotherapy, in Patients Whose Tumors Express PD-L1 (CPS

38. 19 November 2019 Merck Announces First-Quarter 2020 Dividend

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company's common stock for the first quarter

39. 18 November 2019 Ontario and Quebec provide reimbursement for HIV therapies PIFELTRO® (doravirine) and DELSTRIGO® (doravirine/lamivudine/tenofovir disoproxil fumarate)

    Although treatment progress has been made, human immunodeficiency virus (HIV) is still one of the world's most serious public health challenges.i In 2018, approximately 37.9 million people were living with HIV

40. 18 November 2019 Merck and Bayer's Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure

    Vericiguat Reduced the Risk of Heart Failure Hospitalization or Cardiovascular Death in Patients with Worsening Chronic Heart Failure with Reduced Ejection Fraction, Compared to Placebo When Added to Available Heart

41. 15 November 2019 BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration

    Extended Duration Formulation Ensures Cats Receive Broad-Spectrum Parasite Coverage in One Topical Application Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced

42. 14 November 2019 US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review

    AstraZeneca and Merck's Selumetinib Would Become the First Medicine Indicated for the Treatment of Certain Pediatric Patients with NF1 Plexiform Neurofibromas if Approved AstraZeneca and Merck (NYSE:MRK), known as MSD

43. 12 November 2019 NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing authorization to ERVEBO®,

44. 12 November 2019 BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

    Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer:

45. 11 November 2019 Merck's ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

     Authorization Represents Significant Advancement in the Global Response to Ebola Merck Remains Committed to Working with International Health Partners in Ebola Outbreak Response Merck (NYSE:MRK), known as MSD

46. 06 November 2019 NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    AMES, Iowa, Nov. 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on corporate activities.

47. 29 October 2019 Merck Announces Third-Quarter 2019 Financial Results

    Third-Quarter 2019 Worldwide Sales Were $12.4 Billion, an Increase of 15%; Sales Increased 16% Excluding Impact from Foreign Exchange; Growth Driven by Oncology and Human Health Vaccines KEYTRUDA Sales Grew 62% to

48. 24 October 2019 BriaCell Announces Voting Results of the Special Meeting of Shareholders

    BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

49. 21 October 2019 NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

50. 21 October 2019 NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

51. 21 October 2019 NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

52. 21 October 2019 NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

53. 18 October 2019 Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

    Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L (CPS ≥1) Merck (NYSE:MRK), known as MSD outside the United States

54. 18 October 2019 Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion

55. 10 October 2019 NexTech Appoints New Chief Financial Officer

    NEW YORK and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- NexTech AR Solutions (the "Company" or "NexTech") (OTCQB:NEXCF) (CSE:NTAR) (FSE: N29) is pleased to announce that it has appointed Kashif Malik as Chief Financial

56. 08 October 2019 BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

57. 08 October 2019 Merck Issues 2018/2019 Corporate Responsibility Report

    Report Illustrates Merck's Approach to Long-Term Sustainability for Business and Society Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report.

58. 07 October 2019 BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

    Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell's lead candidate, Bria-IMT™ in combination with Incyte's INCMGA00012 and epacadostat in patients with advanced breast cancer.Cancer blocks the immune system pr

59. 02 October 2019 Merck's KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

    KEYTRUDA is First Anti-PD-1 Therapy Approved as Monotherapy and in Combination with Chemotherapy in First-Line Setting for NSCLC in China Merck (NYSE:MRK), known as MSD outside the United States and Canada, today

60. 02 October 2019 FDA Accepts Two Applications for Merck's DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections

    DIFICID® Pediatric Filings Receive Priority Review Classification Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for

61. 01 October 2019 BriaCell Therapeutics Corp. to Clarify Record Date

    BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

62. 01 October 2019 Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 29.

63. 01 October 2019 Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

64. 30 September 2019 Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

    TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A.

65. 30 September 2019 LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)

    Merck and AstraZeneca's LYNPARZA Reduced the Risk of Disease Progression or Death by 51% in Men with Homologous Recombination Repair (HRR) Gene Mutations First Positive Phase 3 Trial Evaluating a Targeted Treatment in

66. 30 September 2019 Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

67. 30 September 2019 Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, Chief Marketing Officer for Merck, is scheduled to present during a fireside chat at the Cantor Fitzgerald 2019

68. 30 September 2019 Pivotal RESTORE-IMI 2 Phase 3 Study of Merck's RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 RECARBRIO™ (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) RESTORE-IMI 2 trial met its primary

69. 29 September 2019 Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

    Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium As Previously Announced, KEYTRUDA Plus Chemotherapy Has Been

70. 29 September 2019 Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 evaluating KEYTRUDA, Merck's anti-PD-1

71. 28 September 2019 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

    AstraZeneca and Merck's LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Based Chemotherapy AstraZeneca and Merck

72. 25 September 2019 BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special 'Targeted Immunotherapy' Issue in Prestigious Journals

    BERKELEY, Calif., and VANCOUVER, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

73. 19 September 2019 BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

    Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress.  Publicly-traded securities of BriaCell Therapeutics Corp.

74. 18 September 2019 Biotech Companies Endeavor to Address Global Health Issues

    NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report

75. 18 September 2019 FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Ra

76. 17 September 2019 FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR), Who Have Disease Progression Following Prior

77. 17 September 2019 FDA Accepts Merck's Biologics License Application (BLA) and Grants Priority Review for V920, the Company's Investigational Vaccine for Ebola Zaire Virus

    Merck Continues to Expand Investigational Supply to Support International Ebola Outbreak Response Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration

78. 10 September 2019 Merck Announces First Nine "Safer Childbirth Cities" Committed to Reducing Maternal Deaths and Narrowing Disparities in the US

    Co-Funders Join Merck for Mothers to Support Newly Formed City-Based Coalitions Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today its funding support of projects in nine cities

79. 10 September 2019 Pooled Analysis Continues to Show Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1

    Findings from Pooled Analysis of KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (Cohort G) Presented at the IASLC 2019 World Conference on Lung Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada,

80. 09 September 2019 Pivotal New Data from Merck's Broad Oncology Portfolio at ESMO 2019 Congress

    Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to be Featured in ESMO Presidential Symposium and Official

81. 05 September 2019 Merck to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories,

82. 04 September 2019 Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities

    The Merck Foundation (the Foundation) has launched HIV Care Connect, a $7 million, five-year initiative to help reduce disparities in access to care and improve health outcomes for persons with HIV living in vulnerable

83. 04 September 2019 European Commission Approves Merck's KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

    European Approval Based on KEYNOTE-426 Trial Results Demonstrating Significant Improvement in Overall Survival with KEYTRUDA in Combination with Axitinib Compared to Sunitinib KEYTRUDA is First Anti-PD-1 Therapy

84. 22 August 2019 Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer

    Pooled Overall Survival (OS) Data from Three Trials with KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Subgroup of Patients with Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Do Not Express PD-L1 New KEYTRUDA